Insights On CONTRACT PHARMA MANUFACTURING

  1. Tech Transfer In Late-Stage OSD Projects: Best Practices From A CDMO 11/7/2025

    Focus on documentation quality, process consistency, and validation are required to transition from development to commercial scale, including capturing tacit knowledge and proactive risk management.

  2. Does A One-Site CDMO Make A Difference In Drug Development? 11/7/2025

    A one-site CDMO streamlines drug development by co-locating R&D, GMP, and manufacturing. This integration accelerates tech transfer and decision-making, significantly compressing project timelines.

  3. Making A Meaningful Impact In AAV 11/7/2025

    Viralgen’s Andy Holt at Meeting on the Mesa 2025 highlighted in-house plasmid manufacturing, expanded commercialization development, and cost reduction in gene therapy manufacturing.

  4. Achieve Speed, Stability, And Compliance In Cell Line Development 11/6/2025

    Partnering with a CDMO that demonstrates innovative and commercially validated cell line development capabilities is essential to protecting your market position and securing investor support.

  5. Smart Input Selection And Process Refinement For iPBMCs 11/5/2025

    Improved iPBMC manufacturing boosts TIL therapy reliability, safety, and affordability through donor screening, process refinements, and performance-based cell selection.

  6. Laminar And Turbulent Mixing Techniques For LNP Formulations Scale Up 11/4/2025

    Explore the critical factors in scaling up lipid nanoparticle (LNP) formulation, comparing the advantages and limitations of both laminar (microfluidic) and turbulent (tee and jet) mixing technologies.

  7. How To Select The Right Bioanalysis CRO For Your Program 11/3/2025

    The right bioanalysis CRO accelerates progress, while the wrong one can derail outcomes. When every provider claims speed and credibility, how do you confidently choose the right partner?

  8. xRNA Production: The Economic Case For Continuous Manufacturing 10/31/2025

    See how a continuous manufacturing platform streamlines production to days, uses real-time quality control, and dramatically cuts costs to accelerate access to new therapies.

  9. Screening T7 Polymerases To Optimize xRNA Yield And Quality 10/31/2025

    Discover how the evolution of T7 polymerase is optimizing in vitro transcription for RNA therapeutics. Learn to balance performance, cost, and supply to make smart choices for your xRNA manufacturing.

  10. Partner Case Study: Accelerating Gene Editing Manufacturing 10/28/2025

    Beam Therapeutics partnered with ElevateBio to manufacture BEAM-101, a novel base editing therapy for sickle cell disease, advancing rapid, high-quality production towards clinical trials.